PT3137479T - Composições de oligonucleótidos e métodos de fabrico das mesmas - Google Patents

Composições de oligonucleótidos e métodos de fabrico das mesmas

Info

Publication number
PT3137479T
PT3137479T PT157858226T PT15785822T PT3137479T PT 3137479 T PT3137479 T PT 3137479T PT 157858226 T PT157858226 T PT 157858226T PT 15785822 T PT15785822 T PT 15785822T PT 3137479 T PT3137479 T PT 3137479T
Authority
PT
Portugal
Prior art keywords
making
methods
same
oligonucleotide compositions
oligonucleotide
Prior art date
Application number
PT157858226T
Other languages
English (en)
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of PT3137479T publication Critical patent/PT3137479T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C12N2310/3145—Phosphoramidates with the nitrogen in 3' or 5'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT157858226T 2014-05-01 2015-04-29 Composições de oligonucleótidos e métodos de fabrico das mesmas PT3137479T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461987396P 2014-05-01 2014-05-01
US201562151909P 2015-04-23 2015-04-23

Publications (1)

Publication Number Publication Date
PT3137479T true PT3137479T (pt) 2023-11-30

Family

ID=54359301

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157858226T PT3137479T (pt) 2014-05-01 2015-04-29 Composições de oligonucleótidos e métodos de fabrico das mesmas

Country Status (32)

Country Link
US (5) US9796747B2 (pt)
EP (2) EP4286519A3 (pt)
JP (6) JP7040892B2 (pt)
KR (3) KR20230088509A (pt)
CN (3) CN117357548A (pt)
AP (1) AP2016009489A0 (pt)
AU (3) AU2015253158B2 (pt)
BR (1) BR112016025196B1 (pt)
CA (1) CA2943888A1 (pt)
CL (4) CL2016002749A1 (pt)
DK (1) DK3137479T3 (pt)
EA (1) EA034882B9 (pt)
ES (1) ES2963740T3 (pt)
FI (1) FI3137479T3 (pt)
HR (1) HRP20231505T1 (pt)
HU (1) HUE064289T2 (pt)
IL (2) IL248044B (pt)
JO (2) JOP20200257A1 (pt)
LT (1) LT3137479T (pt)
MX (2) MX2016014178A (pt)
MY (2) MY178617A (pt)
PE (1) PE20170147A1 (pt)
PH (1) PH12016502080A1 (pt)
PL (1) PL3137479T3 (pt)
PT (1) PT3137479T (pt)
RS (1) RS64860B1 (pt)
SG (2) SG10201911086XA (pt)
SI (1) SI3137479T1 (pt)
TW (2) TWI709406B (pt)
UA (1) UA126108C2 (pt)
WO (1) WO2015168310A1 (pt)
ZA (2) ZA201606624B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485717B2 (en) 2004-07-02 2009-02-03 Geron Corporation Synthesis of protected 3′-amino nucleoside monomers
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
RS60645B1 (sr) * 2015-04-23 2020-09-30 Geron Corp Postupci za pripremu polinukleotida upotrebom kompozicija multivalentne katjonske soli
RS62705B1 (sr) * 2017-07-10 2022-01-31 Geron Corp Poboljšani postupak za pripremanje imetelstata
IL292328A (en) * 2019-10-28 2022-06-01 Geron Corp Succinylate-converted 3-(fatty amido)-2-hydroxy-1-(hydroxy-protected)-propane salts amorphous solids and methods for their preparation
JP2022554244A (ja) 2019-10-28 2022-12-28 ジェロン・コーポレーション ３－パルミトイル－アミド－１，２－プロパンジオールおよび３－パルミトイル－アミド－２－ヒドロキシ－１－ジメトキシトリフェニルメチルエーテル－プロパンの結晶性固体ならびにそれらを作製および使用する方法
CN115315430A (zh) 2020-01-08 2022-11-08 日东电工株式会社 使用了链段型亚磷酰胺化合物的核酸合成法

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4046720A (en) 1974-01-17 1977-09-06 California Institute Of Technology Crosslinked, porous, polyacrylate beads
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4678814A (en) 1981-03-30 1987-07-07 California Institute Of Technology Polyacrolein microspheres
US4413070A (en) 1981-03-30 1983-11-01 California Institute Of Technology Polyacrolein microspheres
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US6448392B1 (en) 1985-03-06 2002-09-10 Chimerix, Inc. Lipid derivatives of antiviral nucleosides: liposomal incorporation and method of use
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US4757141A (en) 1985-08-26 1988-07-12 Applied Biosystems, Incorporated Amino-derivatized phosphite and phosphate linking agents, phosphoramidite precursors, and useful conjugates thereof
US4659774A (en) 1985-11-01 1987-04-21 American Hoechst Corporation Support for solid-phase oligonucleotide synthesis
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
JPH04503957A (ja) 1989-03-07 1992-07-16 ジェネンテク，インコーポレイテッド 脂質とオリゴヌクレオチドの共有結合コンジュゲート
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US6153737A (en) 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6395492B1 (en) 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
EP0537299A1 (en) 1990-03-29 1993-04-21 Gilead Sciences, Inc. Oligonucleotide-transport agent disulfide conjugates
US5420330A (en) 1990-09-07 1995-05-30 Pharmacia P-L Biochemicals Inc. Lipo-phosphoramidites
US5419966A (en) 1991-06-10 1995-05-30 Microprobe Corporation Solid support for synthesis of 3'-tailed oligonucleotides
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5837453A (en) 1992-05-13 1998-11-17 Geron Corporation Telomerase activity assays
US5629154A (en) 1993-11-12 1997-05-13 Geron Corporation Telomerase activity assays
US5489508A (en) 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
IL107150A0 (en) 1992-09-29 1993-12-28 Isis Pharmaceuticals Inc Oligonucleotides having a conserved g4 core sequence
US6087491A (en) 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
US6350853B1 (en) 1993-04-26 2002-02-26 Peter E. Nielsen Conjugated peptide nucleic acids having enhanced cellular uptake
DE4331670A1 (de) 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
DE69434569T2 (de) 1993-10-18 2006-08-24 The Walter And Eliza Hall Institute Of Medical Research, Parkville Verfahren zur erhöhung der überlebensrate von neuronen und dafür verwendbare mittel
US5863726A (en) 1993-11-12 1999-01-26 Geron Corporation Telomerase activity assays
US5726297A (en) 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
US5599922A (en) 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
PL316434A1 (en) 1994-03-18 1997-01-06 Lynx Therapeutics Oligonucleotidic phosphoramides n3'-p5', their compositions, synthesising and hydridising methods as well as immunological properties in respect to nuclease
GB9413035D0 (en) 1994-06-29 1994-08-17 Scras Antisense oligonucleeotides
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
AU696702B2 (en) 1994-07-07 1998-09-17 Geron Corporation Mammalian telomerase
EP0790965A1 (en) 1994-11-07 1997-08-27 HYBRIDON, Inc. Synthesis of ?35 s-labeled oligonucleotides with 3h-1,2-benzodithiol-3-1,1-dioxide
US5760062A (en) 1995-04-18 1998-06-02 Geron Corporation Telomerase inhibitors
US5656638A (en) 1995-04-18 1997-08-12 Geron Corporation Telomerase inhibitors
US5863936A (en) 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US5840490A (en) 1995-06-07 1998-11-24 Mcmaster University Telomerase activity associated with hematological and colorectal malignancies
US5770613A (en) 1995-09-29 1998-06-23 Geron Corporation Telomerase inhibitors
US5767278A (en) 1995-10-06 1998-06-16 Geron Corporation Telomerase inhibitors
US5684143A (en) 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
US5859233A (en) 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
GB9606158D0 (en) 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
US6015710A (en) 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
AU2445997A (en) 1996-04-10 1997-10-29 Lynx Therapeutics, Inc. Telomerase inhibitors
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6444650B1 (en) 1996-10-01 2002-09-03 Geron Corporation Antisense compositions for detecting and inhibiting telomerase reverse transcriptase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6001991A (en) 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
EP0951568A1 (en) 1996-12-20 1999-10-27 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
US5846723A (en) 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US5998604A (en) 1997-09-15 1999-12-07 The Perkin-Elmer Corporation Polynucleotide purification method
JP3722630B2 (ja) 1998-10-28 2005-11-30 パイオニア株式会社 記録再生装置
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
ES2302701T3 (es) * 1999-09-10 2008-08-01 Geron Corporation N3'-p5' tiofosforamidatos oligonucleotidicos: su sintesis y uso.
GB9927674D0 (en) * 1999-11-23 2000-01-19 Aegis Eng Ltd Protective material
US6331399B1 (en) 2000-05-16 2001-12-18 Isis Pharmaceuticals, Inc. Antisense inhibition of tert expression
US7563618B2 (en) 2001-03-23 2009-07-21 Geron Corporation Oligonucleotide conjugates
AU2002245717A1 (en) 2001-03-23 2002-10-08 Geron Corporation Oligonucleotide conjugates
DK1667522T3 (en) 2003-09-09 2018-03-05 Geron Corp MODIFIED OLIGONUCLEOTIDES FOR TELOMERASE INHIBITION
US20120329858A1 (en) * 2010-08-04 2012-12-27 Geron Corporation Modified oligonucleotides for telomerase inhibition
US7485717B2 (en) 2004-07-02 2009-02-03 Geron Corporation Synthesis of protected 3′-amino nucleoside monomers
WO2006023880A2 (en) * 2004-08-23 2006-03-02 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
CA2584984A1 (en) * 2004-10-18 2006-04-27 Codon Devices, Inc. Methods for assembly of high fidelity synthetic polynucleotides
ATE553198T1 (de) 2005-04-15 2012-04-15 Geron Corp Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten
WO2007127163A2 (en) * 2006-04-24 2007-11-08 Geron Corporation Cns-tumor treatment method and composition
PL2101789T3 (pl) 2006-10-30 2015-05-29 Geron Corp Inhibitor telomerazy skojarzony z gemcytabiną do leczenia nowotworu
WO2008094640A2 (en) * 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9106103B2 (en) 2011-09-23 2015-08-11 Eaton Corporation Unintteruptible power supply systems and methods employing on-demand energy storage
US9006630B2 (en) 2012-01-13 2015-04-14 Altasens, Inc. Quality of optically black reference pixels in CMOS iSoCs
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
US20150342982A1 (en) 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها

Also Published As

Publication number Publication date
BR112016025196B1 (pt) 2022-08-02
MX2016014178A (es) 2017-05-04
SI3137479T1 (sl) 2023-11-30
US20180016294A1 (en) 2018-01-18
RS64860B1 (sr) 2023-12-29
US11739114B2 (en) 2023-08-29
JP2023073510A (ja) 2023-05-25
ES2963740T3 (es) 2024-04-01
CL2022000202A1 (es) 2023-02-10
JP2018131453A (ja) 2018-08-23
PH12016502080A1 (en) 2017-01-09
IL268570A (en) 2019-09-26
JP7040892B2 (ja) 2022-03-23
KR20230088509A (ko) 2023-06-19
HUE064289T2 (hu) 2024-02-28
CN117357548A (zh) 2024-01-09
AU2015253158B2 (en) 2019-12-12
US20240150391A1 (en) 2024-05-09
KR20160147768A (ko) 2016-12-23
TWI709406B (zh) 2020-11-11
IL248044B (en) 2019-08-29
LT3137479T (lt) 2023-10-10
TW201622732A (zh) 2016-07-01
EA034882B1 (ru) 2020-04-01
SG10201911086XA (en) 2020-01-30
MY178617A (en) 2020-10-19
WO2015168310A1 (en) 2015-11-05
CN111228288B (zh) 2023-10-20
CN106459134B (zh) 2020-02-18
TW202017574A (zh) 2020-05-16
TWI712413B (zh) 2020-12-11
EP3137479B1 (en) 2023-08-30
HRP20231505T1 (hr) 2024-03-01
DK3137479T3 (da) 2023-11-20
AU2020201707B2 (en) 2022-02-17
MX2021004932A (es) 2021-08-16
NZ724764A (en) 2021-02-26
AU2015253158A1 (en) 2016-10-20
CL2018001213A1 (es) 2018-08-03
EP4286519A2 (en) 2023-12-06
ZA201606624B (en) 2020-12-23
US9796747B2 (en) 2017-10-24
JP2020050670A (ja) 2020-04-02
JO3767B1 (ar) 2021-01-31
PE20170147A1 (es) 2017-04-12
EP3137479A4 (en) 2018-02-07
EA201691786A1 (ru) 2017-04-28
CA2943888A1 (en) 2015-11-05
US20150337314A1 (en) 2015-11-26
FI3137479T3 (fi) 2023-11-28
CL2018001212A1 (es) 2018-08-03
ZA202005857B (en) 2024-01-31
NZ763996A (en) 2021-03-26
IL248044A0 (en) 2016-11-30
CN106459134A (zh) 2017-02-22
EA034882B9 (ru) 2020-07-13
JOP20200257A1 (ar) 2017-06-16
KR102316282B1 (ko) 2021-10-25
KR20210130822A (ko) 2021-11-01
SG11201608226YA (en) 2016-10-28
EP4286519A3 (en) 2024-02-28
MY196927A (en) 2023-05-11
AU2020201707A1 (en) 2020-03-26
AP2016009489A0 (en) 2016-10-31
JP2021182946A (ja) 2021-12-02
EP3137479A1 (en) 2017-03-08
US10392418B2 (en) 2019-08-27
BR112016025196A2 (pt) 2017-12-12
US11299511B2 (en) 2022-04-12
JP7308309B2 (ja) 2023-07-13
IL268570B (en) 2021-10-31
CL2016002749A1 (es) 2017-04-28
AU2022203273A1 (en) 2022-06-02
CN111228288A (zh) 2020-06-05
JP2017514479A (ja) 2017-06-08
US20220306676A1 (en) 2022-09-29
PL3137479T3 (pl) 2024-02-26
US20180016293A1 (en) 2018-01-18
UA126108C2 (uk) 2022-08-17
JP2022044679A (ja) 2022-03-17

Similar Documents

Publication Publication Date Title
HRP20192145T1 (hr) Pripravci nosača-antitijela i metode pripreme i uporabe istih
HK1256225A1 (zh) 寡核苷酸組合物及其方法
HK1255370A1 (zh) 寡核苷酸組合物及其方法
GB2535253B (en) Compositions and methods
GB201513304D0 (en) Compositions and Methods
IL250568A0 (en) Anti-methanogenic preparations and their uses
SG11201707876YA (en) Microalgal compositions and uses thereof
GB201417828D0 (en) New methods and compositions
ZA202104969B (en) Compositions comprising 15-hepe and methods of using the same
ZA202005857B (en) Oligonucleotide compositions and methods of making the same
HK1247136A1 (zh) 包含15-hepe的組合物和其使用方法
HK1243404A1 (zh) 色酰胺組合物和使用方法
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
GB201512996D0 (en) Compositions and methods
GB201514413D0 (en) Compositions and methods
GB201402915D0 (en) Compositions and methods
GB201403212D0 (en) Compositions and methods